argenx SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of argenx SE (NASDAQ:ARGX) have been given an average recommendation of “Moderate Buy” by the twenty-two research firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $639.78.

Several equities analysts have recently weighed in on the stock. Evercore ISI lifted their target price on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Truist Financial lifted their price objective on shares of argenx from $540.00 to $660.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Raymond James reissued a “strong-buy” rating and set a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $617.00 price target on shares of argenx in a research report on Wednesday, November 20th.

Institutional Trading of argenx

Several large investors have recently bought and sold shares of ARGX. Lord Abbett & CO. LLC acquired a new position in shares of argenx during the 3rd quarter worth approximately $88,339,000. Wilmington Savings Fund Society FSB acquired a new position in argenx during the third quarter worth $652,000. Sanctuary Advisors LLC grew its holdings in argenx by 17.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company’s stock valued at $1,119,000 after buying an additional 308 shares in the last quarter. M&T Bank Corp grew its holdings in argenx by 7.2% in the 3rd quarter. M&T Bank Corp now owns 4,307 shares of the company’s stock valued at $2,335,000 after buying an additional 289 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of argenx by 16.9% during the 3rd quarter. MML Investors Services LLC now owns 8,699 shares of the company’s stock worth $4,715,000 after acquiring an additional 1,255 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

Shares of ARGX opened at $626.31 on Monday. The business’s 50-day moving average is $599.42 and its two-hundred day moving average is $532.14. The company has a market capitalization of $37.81 billion, a P/E ratio of -711.72 and a beta of 0.59. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $644.97.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same period last year, the company earned ($1.25) earnings per share. Analysts forecast that argenx will post 2.2 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.